Introduction
The number of melanoma cases worldwide is increasing faster than any other type of cancer. 1 Although surgical removal of melanoma at an early stage is curative, the current medical therapies do not improve survival, once the tumour has disseminated. This warrants alternative approaches, including attempts to activate the immune system, for example, by gene-based therapies. 2 The limited efficacy of nonproliferating viruses for tumour therapy has stimulated the development of replicating viruses as oncolytic agents (for review see Alemany et al , including adenovirus (Ad), [5] [6] [7] herpes simplex virus (HSV), [8] [9] [10] reovirus 11 and vesicular stomatitis virus (VSV). 12, 13 Replicating Ads have been shown to induce tumour reduction in animal models and have entered clinical trials. Injection of the E1B-55 K deleted ONYX-015 Ad into human head and neck tumours combined with chemotherapy, for example, led to a regression of tumours and only minor toxicity in normal tissues, implicating a clear therapeutic benefit in a majority of treated patients. [14] [15] [16] Despite the readily accessible location of many melanoma metastases, no replicating Ad is yet available to target melanoma tumours. A key issue of utilizing oncolytic viruses in cancer therapy is to obtain high levels of viral replication specifically in the tumour tissue, but not in the nearby normal cells. One promising approach to achieve tissuespecific replication of Ad has been accomplished by the insertion of tissue specific promoters upstream of the E1A gene, the major transactivator controlling Ad replication. The use of such promoters allowed restricted replication in prostate, 7 liver 17 and breast tumour cells. 18 We decided to construct an Ad vector with melanomarestricted expression of the E1A gene. Several reports indicated that cell-type-specific expression from inserted heterologous promoters, such as the albumin promoter 19, 20 or the muscle-specific myosin light chain promoter, 21 were compromised by E1A enhancer sequences or additional downstream sequences. 22 To construct a melanoma-specific Ad vector, we deleted large parts of the sequences upstream of E1A and inserted a specific tyrosinase enhancer/promoter construct (TETP), resulting in a vector termed AdDEP-TETP. Our vector still contained the left inverted terminal repeat (ITR) and engineered packaging elements 23, 24 and thus could be propagated normally in helper cells. This virus had reduced cytopathic effects on nonmelanoma cells, but maintained high replicative properties in a panel of melanoma cells, including primary melanoma cultures. Importantly, AdDEP-TETP induced a significant regression of xenotransplanted melanoma tumours upon intratumoural (i.t.) injections, demonstrating the oncolytic potential of this virus.
Materials and methods

Cell culture
The human cervical carcinoma cell line HeLa and the human colon carcinoma cell lines SW480 and DLD-1 were obtained from ATCC. The human melanoma cell lines SK-Mel23 and MeWo were kindly provided by D Schadendorf (DKFZ, Heidelberg, Germany) and originated from L Old (Sloan Kettering, New York, NY, USA). M21-L4 human melanoma cells were obtained from D Cheresh (Scripps Research Institute, La Jolla, USA) and the primary human melanoma cell culture M951004 was used as described earlier. 25, 26 Primary human fibroblasts isolated from human foreskin were kindly provided by J Liu (Department of Dermatology, University Hospital, Zü rich, Switzerland). Human umbilical cord vessel endothelial cells (HUVEC) were obtained from L Jornot (University Hospital, Geneva, Switzerland) and were passaged only once in RPMI 1640 medium plus 10% FCS, 15 mg/ml endothelial cell growth supplement (Upstate-Biotechnology) and 90 mg/ml heparin (Serva). The helper cell line 911 expressing adenoviral E1 proteins was obtained from R Hoeben (Med. Biochemistry, Leiden, Netherlands). 27 Cells were generally maintained in DMEM plus 10% FCS except DLD-1, which were kept in RPMI 1640 plus 10% FCS.
Construction of reporter plasmids and luciferase assays
The luciferase reporter plasmids pGL3 were either promoter-less (pGL3-basic) or contained the SV40 promoter (pGL3-SV40P) to direct luciferase expression (Stratagene Europe, Amsterdam, The Netherlands). The plasmid pGL3-TP was generated by inserting an Xba IXho I-fragment containing the human tyrosinase promoter (kindly provided by CR Goding, Marie Curie Research Institute, Oxted, UK), 28 from bp À300 to bp +80 into the Xho I restriction site of pGL3-basic upstream of the luciferase gene by blunt end ligation. The four tandem repeats of the 200 bp mouse tyrosinase enhancer segment (À12.3 to À12.1 kb relative to the tyrosinase transcription start site) 29 were kindly provided by D Schadendorf (DKFZ, Heidelberg, Germany) and were cloned by Sal I (blunt) and Xba I restriction sites between the Sac I (blunt) and Nhe I sites upstream of the tyrosinase promoter, giving rise to pGL3-4 Â TETP. To construct pGL3-1 Â TETP, a TE monomer PCR-fragment was generated using the primers CGCGGAGCTCTCGA-CAGTTCCTGCCAG and CGATCCCGGGTGCCAGG-ACCCCAGCAGAAG introducing the flanking and unique Sac I and Sma I sites, respectively. This fragment was subsequently cloned into the corresponding sites of pGL3-TP. pGL3-2 Â TETP and pGL3-3 Â TETP were generated making use of these unique restriction sites in combination with the unique Sph I site within the luciferase sequence. The pGL3-9 Â TDE-TP was constructed by exchange of the SV40 promoter (SV40P) from pGL3-9 Â TDE-SV40P by a three-way ligation of the 380 bp Bam HI-Xho I-fragment containing the human tyrosinase promoter, the 3326 bp Xba I-Bgl II fragment of pGL3-9 Â TDE-SV40P and the 1710 bp Xba I-Xho I fragment of pGL3 basic. The pGL3-9 Â TDE-SV40P itself was constructed by cloning two 84 bp fragments encoding 3 Â TDE 30 into pGL3-3 Â TDE-SV40P (kindly provided by R Vile, Mayo Foundation, Rochester, USA). For the determination of promoter activity, cells were grown in 12-well plates to subconfluency and were transiently transfected by lipofectin with 0.5 mg of reporter plasmid and 0.25 mg of pCMVbeta encoding b-galactosidase. Cells were lysed 48 h postinfection (p.i.), and luciferase and b-galactosidase activities were determined according to commercially available protocols (Promega Switzerland, Catalysis AG, Wallisellen).
Construction of adenoviral transfer plasmids
To construct the pAdDEP transfer plasmid, the first part of the E1A open reading frame (ORF) (bp 548-1347) was PCR amplified using the upstream primer #149 ( 0 ) and were subcloned upstream of the packaging sequence into Eco RI and Pst I sites (pBL-ITR-packaging-E1Apart). The Eco RI/Xba I-fragment of pAdSalB encoding the first 1339 bp of Ad5 (R Hoeben, Med. Biochemistry, Leiden, The Netherlands) was replaced by the corresponding sequence containing ITR-packaging-E1Apart resulting in pAdDEP. pAdDEP-TETP was generated by insertion of a 4 Â TETP-encoding Kpn I-Bgl II-fragment derived from pGL3-4 Â TETP into the Bam HI site of pAdDEP by blunt end ligation. Ad5 wt300 was used as control vector. 23 
Generation and purification of replication competent viruses
Ad vectors were generated by homologous recombination between the linearized transfer plasmids (using the Eco RI site) and a Cla I-restricted AdCMV-lacZ viral DNA-fragment (right arm of genome) in 911 helper cells, as described. 31 Viruses were grown to large scale, purified by two subsequent CsCl-gradient centrifugations, dialysed against PBS and plaque-titred on 911 cells, as described. 26 The amount of total particles was determined by OD 260 measurements of SDS-disrupted virus (1.1 Â 10 12 virions/OD 260 ). 32 The ratio of infectious to total virus particles was comparable for all virus preparations (0.01-0.02). Multiplicity of infection (MOI) was defined by the number of infectious particles per cell.
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Real-time quantitative RT-PCR for tyrosinase transcripts
cDNA from various cell samples were amplified by realtime quantitative PCR on a LightCyclert (HoffmannLaRoche, Basel, Switzerland) machine with intron spanning primer pairs specific for GAPDH (upper GGTGAAGGTCGGAGTCAACGG, lower GGTCAT-GAGTCCTTCCACGATACC, annealing at 661C, amplicon 450 bp) and tyrosinase (upper ATGGAACGCCCGA-GGGACCTTTAC, lower TGAGAGGCATCCGCTATCC-CAGTG, annealing at 641C, amplicon 186 bp) as described earlier. 33 External standards for quantification consisted of four serial 1 : 10 dilutions of GAPDH-and tyrosinase-plasmid preparations. The obtained fluorescence signal was plotted against the cycle number for all samples and external standards. A linear standard curve was generated for each run, plotting the crossing point against the log-concentration of the standards. Normalization of estimated tyrosinase amounts was achieved by multiplying with a 'GAPDH-factor' in order to compensate for the variations in quantity and quality of starting mRNA. The experiments were performed in triplicates and means and standard deviations (s.d.) were calculated for each set.
PCR for contaminating wt virus
Viral DNA was isolated from CsCl-purified stocks by proteinase K digestion of about 5 Â 10 10 virus particles in digestion buffer (1 Â TE, 0.5% SDS, 0.1 mg/ml proteinase K) for 2 h at 551C. DNA was extracted once with phenolchloroform (1 : 1, v/v) and once with chloroformisoamyl alcohol (24 : 1, v/v). DNA precipitated with sodium acetate and ethanol (1.5-6 mg) was resuspended in TE. PCR was performed using Ready To Go PCR Beads (Amersham Pharmacia, Piscataway, NJ, USA) applying 40 cycles. To detect (wild type) virus an upstream primer #327 (5 0 TAGTCAGCTGACGTG-TAGTG 3 0 ) coding for E1A promoter sequence and the downstream primer #175 (5 0 CAGTACCTCTTCGAT-CAGC 3 0 ) encoding a sequence within E1A ORF were used, giving rise to a product of 196 bp. To check integrity of the promoter constructs, the upstream primer #115 (5 0 CATCATCAATAATATACCTTATTTTGG 3 0 ) encoding the left end of the Ad genome was combined with primer #175.
Western blot
Approximately 10 6 cells (HeLa and SK-Mel23) were infected at an MOI of 5 and harvested after 24 h by scraping. Cells were pelleted, washed with PBS and total protein lysates prepared in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8), supplemented with protease inhibitors (Mini-Complete, Roche, Basel, Switzerland). The lysates were sheared using a G23 syringe and protein concentrations were determined using the BCA kit (Pierce, Rockford, IL, USA). For Western blot analysis, 40 mg protein of HeLa and SK-Mel23 lysates were separated by 10% SDS-PAGE and electro-transferred to a nylon membrane. The membrane was blocked by TBST (10 mM Tris pH 7.6, 150 mM NaCl, 0.1% Tween-20) plus 5% milk powder and incubated with the monoclonal M73 antibody (kind gift of R Eckner, Institute of Molecular Biology, University of Zü rich), recognizing Ad5 E1A (2 mg/ml in TBST 5% milk, or alternatively, with the monoclonal anti-a-tubulin (Sigma Switzerland, Buchs). E1A proteins were detected by an HRP-conjugated anti-mouse secondary antibody and chemiluminescence (Pierce). Protein bands were densitometrically scanned and analysed using the Image Quant software (Molecular Dynamics, Amersham Berkhamsted, UK) and normalized to the corresponding levels of a-tubulin. Results are expressed relative to E1A-negative AdCMV-GFP control infection.
Cytopathic effect and virus growth experiments
Experiments to assess cytopathic potency were performed in microtiter plate assays. Six serial 10-fold dilutions of the different viruses were plated in a volume of 50 ml in a 96-well dish, starting with a concentration of 2 Â 10 7 plaque forming units (PFU)/ml. All dilutions were prepared in cell culture medium. Cells were diluted to 2 Â 10 5 cells/ml and 50 ml of this suspension added per well (MOIs ranging from 100 to 0.001) and observed daily. When MOI 0.1 of wt Ad5 killed approximately 50% of the cells, the remaining cells were fixed with methanol and UV-treated to inactivate residual virus. Attached cells were then stained with crystal violet and the dye was quantified at 570 nm in a microtiter plate reader taking noninfected cells as the 100% reference value. The MOI inducing 50% cell loss was calculated for each virus and plotted as the ratios of wt Ad-MOI 50 to recombinant virus.
To determine virus infectivity, cultured cells were grown in 24-well plates to subconfluency. HUVEC were plated directly after thawing at a concentration of 10 4 cells/well. Cells were infected at an MOI of 1 in a volume of 0.5 ml. Cells and supernatants were harvested 2, 24, 48, 72, 120 and 168 h p.i. and virus titres determined after three cycles of freeze-thaw by plaque assays on 911 cells.
Animal experiments
HeLa or SK-Mel23 cells were inoculated s.c. into 8-10 weeks old nu/nu Balb/c mice at a dose of 2 Â 10 6 cells in 100 ml. Treatment started when tumours reached a volume (v) of 4100 mm 3 . Viruses were injected at doses of 5 Â 10 8 PFU (50 ml) every fifth day for five treatments in total. Tumour sizes were measured every fifth day and volumes were calculated from v¼d 2 Â D/2 (d representing the short and D the long diameter of the tumour). Animals were killed when tumour volume exceeded 1000 mm 3 . Statistical evaluation of tumour volumes was performed using the unpaired Student's t-test. Statistical evaluation of animal survival was performed using the Kaplan-Meier test calculating the Breslow significance.
Results
Characterization of tyrosinase enhancer/promoter elements
To achieve tissue-specific expression for melanoma cells, we characterized potential tissue-specific enhancer/ promoter elements of the tyrosinase gene. Tyrosinase is a key enzyme of the pigment synthesis pathway and is expressed in most melanoma lesions as well as in melanocytes. 34, 35 Using transient transfections of luciferase reporter constructs, we first tested the potentially melanoma-specific transcriptional activator sequence of the human tyrosinase promoter (TP), 28 the human Oncolytic adenoviruses for melanoma treatment I Peter et al tyrosinase distal element (TDE) 30 and the mouse tyrosinase enhancer (TE). 29, 36 The high sensitivity of luciferase assays allowed the detection of low promoter activities in both melanoma and nonmelanoma cells. This is important, since low levels of E1A protein are sufficient for Ad replication. 37 The TP showed very low activity in nonmelanocytic tumour cells like HeLa (Figure 1a ). In the human melanoma cell line MeWo, the TP alone induced luciferase activity by a factor of 3 above background. When nine copies of TDE were placed upstream of the TP, activity was similarly enhanced in both cell types. In contrast, when one, two, three and four repeats of the mouse tyrosinase enhancer element were placed upstream of the human TP, we obtained a 40-, 135-, 355-and 450-fold induced luciferase activity above background, respectively (Figure 1a) . In a second melanoma cell line SK-Mel23, which was also positive for tyrosinase mRNA expression (Table 1) , luciferase activity was even 2000-fold over background and exceeded the activity induced from the SV40 promoter more than 10-fold (Figure 1b) . In HeLa cells and primary human fibroblasts, on the other hand, only low luciferase levels were obtained with our pGL3-4 Â TETP construct (2-3 fold above background). Additional melanoma and nonmelanoma cells were tested, and yielded similar results (data not shown). As the 4 Â TETP composite promoter gave rise to the highest reporter expression, we decided to engineer a TETP-E1A adenovirus by placing the 4xTETP composite promoter upstream of the E1A gene.
Construction of a melanoma-specific replicating adenovirus
To retain the high specificity of the pGL3-4 Â TETP construct in an adenoviral vector, we eliminated transcriptional regulatory sequences located upstream of E1A. Some enhancer elements have been defined in the leftmost 500 bp of the Ad genome, and the numerous minor transcriptional start sites, used at various times during infection, reflect a rather complex regulation of E1A expression 38 ( Figure 2a) . Accordingly, all the mutations introduced previously to diminish E1A transcription, also affected Ad replication and DNApackaging. The latter is mediated by elements (A I to A VII) located between the ITR and the E1A ORF. 39 We therefore designed two deletions to remove the E1A basal promoter elements and the enhancer sequences necessary to activate expression of E1A (E I) or all early genes (E II). One deletion spanned bp 108-334 and the other one 381-547 (Figure 2b) . In order to retain DNApackaging capacity, we inserted duplicated elements A V to A VI encompassing nucleotides 334-385, as reported previously 23, 24 and also inserted a Bam HI restriction site 12 bp upstream of the E1A translation start site to allow insertion of the 4 Â TETP composite promoter. The vector AdDEP-TETP (Figure 2c ) was generated by inserting TETP upstream of E1A. Notably, segment 1-448 bp is present in E1A/E1B-deleted first-generation Ads vectors. 40 Recombinant AdDEP-TETP virus was generated by homologous recombination 41 and amplified in E1A-expressing 911 helper cells as described earlier. 26 In promoter (pGL3-SV40P) or the tyrosinase enhancer/promoter construct (pGL3-4xTETP). Results were determined as described above. ), CsCl-purified virus stocks were analysed by PCR for wt Ad5 contamination. PCR primers were designed to amplify between the E1A promoter and the E1A coding region, resulting in a 196 bp product in case of the wt Ad5, but in no product for the AdDEP-TETP vector, as the corresponding promoter sequence was deleted. The sensitivity of detecting wt DNA was 1 fg of wt DNA in 1 ng of recombinant virus DNA. No contaminating virus was detected at this sensitivity in the AdDEP-TETP virus preparation (data not shown). A second set of primers was designed to amplify between the left ITR and the E1A coding region to verify the correct length of the inserted promoter. The nature of the viral DNA was found to be correct (data not shown).
E1A protein expression in adenovirus-transduced melanoma cells
To test the specificity of the tyrosinase enhancer/ promoter construct in the Ad context, we first analysed the expression of E1A proteins. HeLa and the melanoma cells SK-Mel23 were infected with either wt Ad5, the E1/ E3 deleted first-generation vector AdCMV-GFP or the E3-deleted AdDEP-TETP. E1A proteins were determined by Western blot analysis using the M73 mouse monoclonal antibody 42 ( Figure 3a) , and standardized to the amounts of endogenous a-tubulin (Figure 3b ). As expected, M73 stained several bands of 30-55 kDa, corresponding to the translation products of 9S, 10S, 11S, 12S, and 13S E1A mRNAs, respectively. 43 Densitometric quantifications indicated that E1A proteins were induced more than 50-fold in wt Ad5 as well as in AdDEP-TETP-infected SK-Mel23 cells, when compared to E1A-deleted AdCMV-GFP-infected cells (background Oncolytic adenoviruses for melanoma treatment I Peter et al control). As expected, HeLa cells infected with wt Ad5 led to substantial, approx. 400-fold induced E1A levels, whereas AdDEP-TETP-mediated E1A expression was 10-fold induced, when compared to background control, respectively.
Lytic replication of AdDEP-TETP
We next tested the ability of the AdDEP-TETP virus to specifically induce cytopathic effects in a panel of CAR-positive and easily transducible human tumour cells. Cells were plated in 96-well dishes, infected with serially diluted viruses, and MOIs leading to 50% cell loss (ie, cell death) were determined. Figure 4 shows the ratio of MOI 50 of wt Ad5 to recombinant viruses. Values o1 indicate reduced efficacy of the recombinant virus compared to wt Ad5 and values 41 indicate higher efficiency of recombinant viruses. Both recombinant AdCMV-GFP and AdDEP-TETP were similarly efficient as wt Ad5 in detaching E1A/B expressing 911 cells (Figure 4a ). To induce cytopathic effects in three nonmelanocytic tumour cells (HeLa, SW480 and DLD-1), 50-100 times more AdDEP-TETP were required than wt Ad5. A different picture emerged for the tyrosinase-positive melanoma cells. In SK-Mel23 and M21-L4, AdDEP-TETP had similar cytolytic effects as wt Ad5 and a slightly reduced cytolytic effect in MeWo cells and a somewhat increased cytolytic effect in M951004 cells (Figure 4b ). The replication efficiency of the E1-deleted AdCMV-GFP was 2-3 orders of magnitude lower than wt Ad5 in all cell types, as expected. We next measured the production of infectious particles in melanoma and nonmelanoma cells, including primary cells. Melanoma (SK-Mel23), nonmelanoma (HeLa), primary human umbilical cord vessel endothelial cells (HUVEC) and primary fibroblasts were infected with MOI 1. HUVEC and fibroblasts were included in this experiment, as they represent a more relevant primary cell type. Note that HUVEC and fibroblasts could not be included in the cytotoxicity assays above, as they stained very weakly. Except fibroblasts, which express low levels of CAR, all other cells express substantial amounts of CAR. Samples were collected at different time points (up to 7 days p.i.) and plaque-titred on 911 helper cells. In all nonmelanoma cells, AdDEP-TETP titres were 60-1000 times lower than wt Ad5 titres ( Figure 5 ). In SK-Mel23 melanoma cells, however, AdDEP-TETP titres were comparable to wt Ad5 and the growth curves were almost identical. As expected, AdCMV-GFP did not grow in any of these cells. Taken together, these data indicate that the AdDEP-TETP virus has reduced cytopathic effects in nonmelanoma cells, but maintains high replicative properties in melanoma cells.
AdDEP-TETP induces regression of xenografted melanoma tumours
We next tested the therapeutic efficacy of AdDEP-TETP in an animal xenotransplantation melanoma model. Immune-deficient nude mice were used to induce s.c. HeLa and SK-Mel23-derived tumours, respectively. Tumours were grown to a diameter of about 7 mm, followed by repeated i.t. injections of 5 Â 10 8 PFU of AdDEP-TETP, wt Ad5 or AdCMV-GFP. Injections of wt Ad5 led to a significant, but transient regression of aggressively growing HeLa tumours, whereas AdCMV-GFP and AdDEP-TETP injections had no effect (Figure 6a ). In contrast, wt Ad5 or AdDEP-TETP abolished the growth of melanomas and AdDEP-TETPinduced tumour regression in five out of five animals (Figure 6b ). The kinetics of untreated tumour growth of both types was similar to the growth of AdCMV-GFPtreated tumours (data not shown). Tumours did not completely disappear in the AdDEP-TETP and Ad wt treatment groups, but they maintained a stable size and did not affect the AdDEP-TETP-treated animals during the 200 days observation period (Figure 6c ). Within the limits of the nude mouse experimental system, this indicates an effective oncolytic potential of AdDEP-TETP. We conclude that AdDEP-TETP has significant therapeutic potential for killing melanoma tumours in vitro and in vivo. Oncolytic adenoviruses for melanoma treatment I Peter et al
Discussion
Conditionally replicating Ad vectors have substantial promise for the treatment of prostate and hepatocellular carcinomas. Thus, corresponding Ad vectors with tissuespecific promoters upstream of the immediate early viral transactivator E1A are entering clinical trials. 7, 17, 44 Here, we describe a novel melanoma-specific replicating Ad, whose E1A gene is relatively tightly controlled by a composite enhancer/promoter consisting of the human tyrosinase promoter and four copies of the mouse tyrosinase enhancer. Tyrosinase is a key enzyme of the pigment synthesis pathway and is expressed in most melanoma lesions 34, 35 and in melanocytes. Combining four copies of the mouse tyrosinase enhancer 29, 36 with a 380 bp fragment of the human tyrosinase promoter, 28 we found a highly specific, maximal 2000-fold increase of promoter activity in transient luciferase reporter assays, when compared to nonmelanoma HeLa cells. It has previously been reported that adding two copies of the mouse tyrosinase enhancer to the human tyrosinase promoter increased the promoter activity up to 500-fold relative to the TP alone, without loss of specificity. 45 A thorough comparison of these data with ours is however complicated by the fact that the human tyrosinase promoter used by Park et al 45 was of different length (529 bp) than ours, and different cell lines were used to perform reporter assays. Similarly, a construct containing 3 Â TDE in combination with the 380 bp human tyrosinase promoter gave rise to high-level and tissue-specific expression of encoded GM-CSF; however, this construct was stably integrated by the use of a retroviral system. 46 A recombinant Ad expressing b-Gal under the control of two copies of the mouse tyrosinase enhancer in combination with a 770 bp mouse TP gave rise to 100-200 fold higher expression in melanoma cells compared to nonmelanoma cells. 47 As in our assays the 4 Â TETP composite promoter gave rise to the highest reporter expression, we decided to use this promoter to restrict E1A expression to melanoma cells.
A tight control of E1A expression in Ad-infected cells is complicated by the fact that sequences flanking the E1 genes may influence and deregulate the activity of a nearby inserted cellular promoter, thus compromising the tissue specificity of such heterologous promoters. [19] [20] [21] [22] 48 In addition, the E1A protein appears to regulate its own expression. 49 We therefore deleted large parts of the endogenous Ad E1A enhancer/promoter sequences upstream of E1A and generated the AdDEP-TETP recombinant virus. In melanoma cells this virus gave rise to similar cytolytic activity and virus production when compared to wt Ad5. In nonmelanoma cells, the cytolytic activity and virus production of this vector was approximately two logs lower compared to wt Ad5. Consistent with these results, the E1A enhancer-deleted virus gave rise to substantially lower E1A protein levels in nonmelanoma cells. The difference in the cytolytic activity of the AdDEP-TETP towards the four different melanoma cultures did not correlate with the tyrosinase Oncolytic adenoviruses for melanoma treatment I Peter et al expression levels measured in these cells (Table 1) , which varied by no more than three-fold. It is presently unknown as to which additional factors are involved in determining the efficiency of the composite TETP enhancer/promoter. In fact, one of the additional primary melanoma cultures tested in our system turned out to be positive for the TETP-controlled luciferase reporter expression, but it was completely negative for Oncolytic adenoviruses for melanoma treatment I Peter et al tyrosinase mRNA and protein expression (not shown), suggesting that expression of transcription factors such as the microphthalmia-associated transcription factor 30 is a more reliable indicator for the efficacy of the AdDEP-TETP vector.
When the AdDEP-TETP virus was injected into xenotransplanted melanomas, a significant regression of tumours was observed, compared to control treatment. The observed effect was cell-type specific, as similar treatment of HeLa-derived tumours did not lead to tumour regression, demonstrating the oncolytic potential of this virus in this mouse model. Why the AdDEP-TETP virus was slightly more efficient than Ad wt is unknown, although these vectors displayed similar growth characteristics in cell culture. It is possible that immunosuppressive genes of the E3 region responsible for downregulation of Fas 50 or resistance to tumour necrosis factor alpha 51 are in part responsible for this difference, although the inclusion of E3 may also boost lytic viral release 52 because of the presence of genes encoding cell-enhanced death at a late stage of infection. 53 The effect found here may be a special feature of the SK-Mel23 tumour model, and further experiments are needed to elucidate the role of the different E3 region genes in tumour regression.
In conclusion, we show that AdDEP-TETP has significant therapeutic potential because of the efficient killing of melanoma tumours in vitro and in vivo. Additional experiments are needed to investigate whether this virus is capable of replicating in other tyrosinase-expressing cells such as normal melanocytes, neural-derived tissues of the cochlea and eye, 54 gliomas and normal brain tissue. 55 However, as pre-existing neutralizing anti-Ad antibodies have been shown to influence intravenous injection of Ad in nude mice, 56 it is reasonable to assume that a far-reaching viral dissemination is inhibited and that the cytolytic activity might be restricted to the primarily injected tumour mass. This emphasizes the importance of additional, complementary strategies to target the viral particles to tumour cells by virtue of the primary Ad receptor CAR, integrin coreceptors and the associated signalling pathways ensuring efficient endocytosis and viral delivery to the nuclear membrane and into the nucleus. [57] [58] [59] As only a fraction of primary melanoma expresses CAR, 26 extension of viral tropism to CAR-less melanoma cells will also be crucial. An effective antitumour immune response might be boosted further by inclusion of regulatable genes expressing therapeutic and/or immunostimulatory molecules.
